Novavax to Receive up to $388 Million Funding from CEPI for COVID-19 Vaccine Development and Manufacturing
- Funds clinical development of NVX-CoV2373 through Phase 2
- Supports rapid scale-up of vaccine manufacturing
- Allows for increased production of Matrix-M adjuvant
- Reserves global large-scale manufacturing capacity
“CEPI plays a vital role in advancing innovative technologies against the COVID-19 pandemic. Their partnership and support allows
- A Phase 1/2 clinical trial with the Phase I portion starting this month in
Australiaand the Phase 2 portion conducted in multiple countries following successful Phase 1 top-line results that are expected in July.
- Process development for scaled-up production to potentially allow manufacturing of up to 100 million vaccine doses by end of 2020.
- Access to large-scale manufacturing capacity in multiple countries with a goal of potentially producing over one billion doses during 2021.
“The expansion of our partnership with
SARS-CoV-2 first appeared in late 2019 in
Novavax’ patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response and helping an immunized person make antibodies against the virus.
CEPI is an innovative partnership between public, private, philanthropic, and civil society organizations, launched at
Before the emergence of COVID-19 CEPI's priority diseases included Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also invested in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (Disease X).
Statements herein relating to the future of
Source: Novavax, Inc.